Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**169Yb-DTPA** is a chelate complex consisting of the radioisotope ytterbium-169 (^169Yb) bound to diethylenetriaminepentaacetic acid (DTPA, also called pentetic acid). DTPA acts as a chelator, forming a highly stable complex with metal ions such as radioactive ytterbium. The compound is classified as a radiopharmaceutical, used primarily for diagnostic or therapeutic purposes through targeted radiation delivery. The chelator DTPA securely binds the radioisotope, enabling its use in medical imaging (such as gamma scintigraphy) or as a local radiotherapeutic agent due to the emission of gamma rays by ^169Yb. Mechanistically, DTPA (pentetic acid) acts by binding metal ions, forming stable complexes that can be used for decorporation therapy or, when radiolabeled, for radiodiagnostic or radiotherapeutic purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 169Yb-DTPA.